BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 14741071)

  • 1. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
    Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
    Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers.
    Anderson DM; Shelley S; Crick N; Buraglio M
    J Clin Pharmacol; 2002 Dec; 42(12):1358-65. PubMed ID: 12463731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
    Huang HL; Vaidyanathan S; Yeh CM; Bizot MN; Dieterich HA; Dole WP; Howard D
    Curr Med Res Opin; 2008 Sep; 24(9):2449-56. PubMed ID: 18662494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide.
    Niemi M; Neuvonen M; Juntti-Patinen L; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2003 Jul; 74(1):25-31. PubMed ID: 12844132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ
    Br J Clin Pharmacol; 2004 May; 57(5):592-9. PubMed ID: 15089812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
    Schwartz JI; Bugianesi KJ; Ebel DL; De Smet M; Haesen R; Larson PJ; Ko A; Verbesselt R; Hunt TL; Lins R; Lens S; Porras AG; Dieck J; Keymeulen B; Gertz BJ
    Clin Pharmacol Ther; 2000 Dec; 68(6):626-36. PubMed ID: 11180023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
    Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
    J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium.
    Modi NB; Kell S; Simon M; Vargas R
    J Clin Pharmacol; 2005 Aug; 45(8):919-26. PubMed ID: 16027402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Van Hecken A; Depré M; Verbesselt R; Wynants K; De Lepeleire I; Arnout J; Wong PH; Freeman A; Holland S; Gertz B; De Schepper PJ
    J Clin Pharmacol; 1999 May; 39(5):495-500. PubMed ID: 10234597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of nateglinide taken with food on gastric emptying rates in healthy subjects.
    Anderson D; Shelley S; Kellett N; Marshall D; Nimmo W
    Clin Ther; 2003 Jun; 25(6):1722-38. PubMed ID: 12860494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
    Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI; Dunbar S; Yuan J; Li S; Gipson A; Rosko K; Johnson-Levonas AO; Lasseter KC; Addy C; Stoch AS; Wagner JA
    Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics.
    de Hoon JN; Thijssen HH; Beysens AJ; Van Bortel LM
    Br J Clin Pharmacol; 1997 Oct; 44(4):399-401. PubMed ID: 9354316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI; Liu F; Stroh M; Gipson A; Johnson-Levonas AO; Lasseter KC; Lai E; Wagner JA
    Am J Ther; 2009; 16(3):215-23. PubMed ID: 19454860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of acenocoumarol pharmacodynamics.
    Morin S; Bodin L; Loriot MA; Thijssen HH; Robert A; Strabach S; Verstuyft C; Tregouet DA; Dubert L; Laurent-Puig P; Funck-Brentano C; Jaillon P; Beaune PH; Becquemont L
    Clin Pharmacol Ther; 2004 May; 75(5):403-14. PubMed ID: 15116053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.